A French SME has developed a personalized medicine software platform focused to improve the management of inflammatory diseases in rheumatology.
From a simple blood sample, the platform predicts the effectiveness of a treatment before its prescription based on the analysis of specifics biomarkers of the patient. The French SME is looking for a research partner specialized in blood samples and autoimmune diseases in order to test the performance of the platform within an Eurostars project
Rheumatoid Arthritis (RA) is a progressive autoimmune disease that, often over a course of more than 20 years, causes increasing levels of disability and pain to patients (33.4 million affected persons). The choice of the biotherapy to treat this disease is difficult for the doctors, as they lack medical tools to select the best possible biotherapy for the patient, and as a result they try their luck by giving random biotherapies.
In most cases treatment is initiated with Methotrexate, a cost-effective (240/year) anti-rheumatic drug. However, only 55% of patients remain on this therapy 2-year after the diagnosis. Patients whose treatment by methotrexate has failed to give an adequate response become eligible for the more expensive biotherapy treatment (~10,000/year).
The lack of tools to select the appropriate biotherapy leads to two serious problems:
- Long period of trials and failures (up to 18 months) and, as time goes by, the chances of patient recovery diminish.
- About 35% of RA patients do not respond to prescribed biotherapy.
In order to solve this problem, a French medtech SME has developed an innovative a personalized medicine software platform focused to improve the management of inflammatory diseases in rheumatology and provide the doctors with the necessary decision tool.
From a simple blood sample, the platform predicts the effectiveness of a treatment before its prescription based on the analysis of specifics biomarkers of the patient.
The French SME wants to set up a Eurostars project for the call deadline of the 13th of Septembre, which will allow to validate the performance of the platform and the associated biomarkers thanks to blood samples provided by the partner. The partner will have a crucial role in counselling the French SME on the biomarker choice and will be able to participate in the evaluation of medical treatments of biotherapies for Rheumatoid Arthritis.
The Eurostars project should last around 18 - 20 months.
EoI deadline: 13 July 2018
- Specific area of activity of the partner: Type: Biotech/Pharma/Medtech companies with access to a biobank specializing in rheumatoid arthritis and other autoimmune diseases.
Role: to allow the assessment of the biomarkers necessary for the device in RA patient samples to validate the performance of the algorithms for biologics response prediction in rheumatology.
The partner will play a crucial role in the selection and validation of the biomarkers, and in the evaluation of the appropriate biotherapy of rheumatoid patients.
A licence agreement can be discussed as a result of the project.
Prototype available for demonstration
Evaluation scheme: Continuous submission scheme
Acronym: RA Biobank
Coordinator required: No